Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Review of the novelties presented at the 2018 ECTRIMS Congress: 11th Post-ECTRIMS Meeting (II).

Fernandez O, Tintore M, Saiz A, Calles-Hernandez MC, Comabella M, Ramio-Torrenta L, Oterino A, Izquierdo G, Tellez N, Garcia-Merino JA, Brieva L, Arnal-Garcia C, Aladro Y, Mendibe-Bilbao MM, Meca-Lallana JE, Romero-Pinel L, Martinez-Gines ML, Arroyo R, Oreja-Guevara C, Costa-Frossard L, Carrascal P, Rodriguez-Antiguedad A.

Rev Neurol. 2019 Jun 1;68(11):468-479. doi: 10.33588/rn.6811.2019121. Review. Spanish, English.

2.

[Review of the novelties presented at the 2018 ECTRIMS Congress: 11th Post-ECTRIMS Meeting (I)].

Fernandez O, Tintore M, Saiz A, Calles-Hernandez MC, Comabella M, Ramio-Torrenta L, Oterino A, Izquierdo G, Tellez N, Garcia-Merino JA, Brieva L, Arnal-Garcia C, Aladro Y, Mendibe-Bilbao MM, Meca-Lallana JE, Romero-Pinel L, Martinez-Gines ML, Arroyo R, Oreja-Guevara C, Costa-Frossard L, Carrascal P, Rodriguez-Antiguedad A.

Rev Neurol. 2019 May 16;68(10):431-441. doi: 10.33588/rn.6810.2019120. Review. Spanish.

3.

Management strategies for female patients of reproductive potential with multiple sclerosis: An evidence-based review.

Coyle PK, Oh J, Magyari M, Oreja-Guevara C, Houtchens M.

Mult Scler Relat Disord. 2019 Apr 5;32:54-63. doi: 10.1016/j.msard.2019.04.003. [Epub ahead of print] Review.

4.

Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings.

Barclay K, Carruthers R, Traboulsee A, Bass AD, LaGanke C, Bertolotto A, Boster A, Celius EG, de Seze J, Cruz DD, Habek M, Lee JM, Limmroth V, Meuth SG, Oreja-Guevara C, Pagnotta P, Vos C, Ziemssen T, Baker DP, Wijmeersch BV.

Front Neurol. 2019 Mar 22;10:253. doi: 10.3389/fneur.2019.00253. eCollection 2019. Review.

5.

Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial.

Zubizarreta I, Flórez-Grau G, Vila G, Cabezón R, España C, Andorra M, Saiz A, Llufriu S, Sepulveda M, Sola-Valls N, Martinez-Lapiscina EH, Pulido-Valdeolivas I, Casanova B, Martinez Gines M, Tellez N, Oreja-Guevara C, Español M, Trias E, Cid J, Juan M, Lozano M, Blanco Y, Steinman L, Benitez-Ribas D, Villoslada P.

Proc Natl Acad Sci U S A. 2019 Apr 23;116(17):8463-8470. doi: 10.1073/pnas.1820039116. Epub 2019 Apr 8.

6.

Antiphospholipid Antibodies Overlapping in Isolated Neurological Syndrome and Multiple Sclerosis: Neurobiological Insights and Diagnostic Challenges.

D'Angelo C, Franch O, Fernández-Paredes L, Oreja-Guevara C, Núñez-Beltrán M, Comins-Boo A, Reale M, Sánchez-Ramón S.

Front Cell Neurosci. 2019 Mar 19;13:107. doi: 10.3389/fncel.2019.00107. eCollection 2019.

7.

Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).

Vukusic S, Brassat D, de Seze J, Izquierdo G, Lysandropoulos A, Moll W, Vanopdenbosch L, Arque MJ, Kertous M, Rufi P, Oreja-Guevara C.

Mult Scler Relat Disord. 2019 Apr;29:7-14. doi: 10.1016/j.msard.2019.01.019. Epub 2019 Jan 6.

PMID:
30654246
8.

Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study.

Nguyen AL, Havrdova EK, Horakova D, Izquierdo G, Kalincik T, van der Walt A, Terzi M, Alroughani R, Duquette P, Girard M, Prat A, Boz C, Sola P, Ferraro D, Lugaresi A, Lechner-Scott J, Barnett M, Grand'Maison F, Grammond P, Ramo-Tello C, Turkoglu R, McCombe P, Pucci E, Trojano M, Granella F, Spitaleri D, Van Pesch V, Soysal A, Oreja-Guevara C, Verheul F, Vucic S, Hodgkinson S, Slee M, Ampapa R, Prevost J, Menoyo JLS, Skibina O, Solaro C, Olascoaga J, Shaw C, Madsen KG, Naidoo K, Hyde R, Butzkueven H, Jokubaitis V; MSBase Study Group.

Mult Scler Relat Disord. 2019 Feb;28:235-243. doi: 10.1016/j.msard.2019.01.003. Epub 2019 Jan 3.

PMID:
30623864
9.

Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting.

Albrecht P, Bjørnå IK, Brassat D, Farrell R, Feys P, Hobart J, Hupperts R, Linnebank M, Magdič J, Oreja-Guevara C, Pozzilli C, Salgado AV, Ziemssen T.

Ther Adv Neurol Disord. 2018 Oct 5;11:1756286418803248. doi: 10.1177/1756286418803248. eCollection 2018. Review.

10.

Three-Tesla MRI does not improve the diagnosis of multiple sclerosis: A multicenter study.

Hagens MHJ, Burggraaff J, Kilsdonk ID, de Vos ML, Cawley N, Sbardella E, Andelova M, Amann M, Lieb JM, Pantano P, Lissenberg-Witte BI, Killestein J, Oreja-Guevara C, Ciccarelli O, Gasperini C, Lukas C, Wattjes MP, Barkhof F; MAGNIMS Study Group.

Neurology. 2018 Jul 17;91(3):e249-e257. doi: 10.1212/WNL.0000000000005825. Epub 2018 Jun 20.

11.

Non-inflammatory causes of emergency consultation in patients with multiple sclerosis.

Rodríguez de Antonio LA, García Castañón I, Aguilar-Amat Prior MJ, Puertas I, González Suárez I, Oreja Guevara C.

Neurologia. 2018 May 26. pii: S0213-4853(18)30095-1. doi: 10.1016/j.nrl.2018.02.006. [Epub ahead of print] English, Spanish.

12.

Familial multiple sclerosis and association with other autoimmune diseases.

Pytel V, Matías-Guiu JA, Torre-Fuentes L, Montero P, Gómez-Graña Á, García-Ramos R, Moreno-Ramos T, Oreja-Guevara C, Fernández-Arquero M, Gómez-Pinedo U, Matías-Guiu J.

Brain Behav. 2017 Dec 19;8(1):e00899. doi: 10.1002/brb3.899. eCollection 2018 Jan.

13.

Systematic review of the safety and effectiveness of peripheral neurostimulation of the sphenopalatine ganglion for the treatment of refractory chronic cluster headache.

Sánchez-Gómez LM, Polo-deSantos M, Pinel-González A, Oreja-Guevara C, Luengo-Matos S.

Neurologia. 2018 Jan 12. pii: S0213-4853(17)30369-9. doi: 10.1016/j.nrl.2017.11.002. [Epub ahead of print] English, Spanish.

14.

Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre study.

Hagens MH, Burggraaff J, Kilsdonk ID, Ruggieri S, Collorone S, Cortese R, Cawley N, Sbardella E, Andelova M, Amann M, Lieb JM, Pantano P, Lissenberg-Witte BI, Killestein J, Oreja-Guevara C, Wuerfel J, Ciccarelli O, Gasperini C, Lukas C, Rovira A, Barkhof F, Wattjes MP; MAGNIMS Study Group.

Mult Scler. 2019 Mar;25(3):352-360. doi: 10.1177/1352458517751647. Epub 2018 Jan 12.

15.

Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group.

Members of the MS in the 21st Century Steering Group:, Rieckmann P, Centonze D, Elovaara I, Giovannoni G, Havrdová E, Kesselring J, Kobelt G, Langdon D, Morrow SA, Oreja-Guevara C, Schippling S, Thalheim C, Thompson H, Vermersch P, Aston K, Bauer B, Demory C, Giambastiani MP, Hlavacova J, Nouvet-Gire J, Pepper G, Pontaga M, Rogan E, Rogalski C, van Galen P, Ben-Amor AF.

Mult Scler Relat Disord. 2018 Jan;19:153-160. doi: 10.1016/j.msard.2017.11.013. Epub 2017 Nov 21.

16.

Functional Components of Cognitive Impairment in Multiple Sclerosis: A Cross-Sectional Investigation.

Matias-Guiu JA, Cortés-Martínez A, Valles-Salgado M, Oreja-Guevara C, Pytel V, Montero P, Moreno-Ramos T, Matias-Guiu J.

Front Neurol. 2017 Nov 28;8:643. doi: 10.3389/fneur.2017.00643. eCollection 2017.

17.

Inhibition of neurogenesis in a case of Marburg variant multiple sclerosis.

Oreja-Guevara C, Gómez-Pinedo U, García-López J, Sánchez-Sánchez R, Valverde-Moyano R, Rabano-Gutierrez A, Matías-Guiu JA, González-Suárez I, Matías-Guiu J.

Mult Scler Relat Disord. 2017 Nov;18:71-76. doi: 10.1016/j.msard.2017.09.024. Epub 2017 Sep 22.

PMID:
29141824
18.

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.

Kalincik T, Manouchehrinia A, Sobisek L, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Girard M, Prat A, Duquette P, Grammond P, Sola P, Hupperts R, Grand'Maison F, Pucci E, Boz C, Alroughani R, Van Pesch V, Lechner-Scott J, Terzi M, Bergamaschi R, Iuliano G, Granella F, Spitaleri D, Shaygannejad V, Oreja-Guevara C, Slee M, Ampapa R, Verheul F, McCombe P, Olascoaga J, Amato MP, Vucic S, Hodgkinson S, Ramo-Tello C, Flechter S, Cristiano E, Rozsa C, Moore F, Luis Sanchez-Menoyo J, Laura Saladino M, Barnett M, Hillert J, Butzkueven H; MSBase Study Group.

Brain. 2017 Sep 1;140(9):2426-2443. doi: 10.1093/brain/awx185.

PMID:
29050389
19.

Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.

Lorscheider J, Jokubaitis VG, Spelman T, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Trojano M, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Pucci E, Boz C, Sola P, Ferraro D, Spitaleri D, Lechner-Scott J, Terzi M, Van Pesch V, Iuliano G, Bergamaschi R, Ramo-Tello C, Granella F, Oreja-Guevara C, Butzkueven H, Kalincik T; MSBase Study Group.

Neurology. 2017 Sep 5;89(10):1050-1059. doi: 10.1212/WNL.0000000000004330. Epub 2017 Aug 9.

20.

Estimate of the cost of multiple sclerosis in Spain by literature review.

Fernández O, Calleja-Hernández MA, Meca-Lallana J, Oreja-Guevara C, Polanco A, Pérez-Alcántara F.

Expert Rev Pharmacoecon Outcomes Res. 2017 Aug;17(4):321-333. doi: 10.1080/14737167.2017.1358617. Epub 2017 Jul 28. Review.

PMID:
28726515
21.

Review of the novelties from the 32nd ECTRIMS Congress, 2016, presented at the 9th Post-ECTRIMS Meeting (II).

Fernandez O, Oterino A, Oreja-Guevara C, Prieto JM, Mendibe-Bilbao MM, Garcia-Merino JA, Ramio-Torrenta L, Ginestal R, Meca-Lallana JE, Romero-Pinel L, Munoz D, Oliva-Nacarino P, Calles-Hernandez MC, Izquierdo G, Martinez-Gines ML, Saiz A, Comabella M, Casanova-Estruch B, Brieva L, Arroyo R, Rodriguez-Antiguedad A.

Rev Neurol. 2017 Jul 16;65(2):75-84. Spanish, English.

PMID:
28675259
22.

Review of the novelties from the 32nd ECTRIMS Congress, 2016, presented at the 9th Post-ECTRIMS Meeting (I).

Fernandez O, Oterino A, Oreja-Guevara C, Prieto JM, Mendibe-Bilbao MM, Garcia-Merino JA, Ramio-Torrenta L, Ginestal R, Meca-Lallana JE, Romero-Pinel L, Munoz D, Oliva-Nacarino P, Calles-Hernandez MC, Izquierdo G, Martinez-Gines ML, Saiz A, Comabella M, Casanova-Estruch B, Brieva L, Arroyo R, Rodriguez-Antiguedad A.

Rev Neurol. 2017 Jul 1;65(1):31-40. Review. Spanish, English.

23.

New insights into the burden and costs of multiple sclerosis in Europe: Results for Spain.

Oreja-Guevara C, Kobelt G, Berg J, Capsa D, Eriksson J; European Multiple Sclerosis Platform.

Mult Scler. 2017 Aug;23(2_suppl):166-178. doi: 10.1177/1352458517708672.

PMID:
28643597
24.

Amyloid PET in pseudotumoral multiple sclerosis.

Matías-Guiu JA, Cabrera-Martín MN, Cortés-Martínez A, Pytel V, Moreno-Ramos T, Oreja-Guevara C, Carreras JL, Matías-Guiu J.

Mult Scler Relat Disord. 2017 Jul;15:15-17. doi: 10.1016/j.msard.2017.05.002. Epub 2017 May 2.

PMID:
28641766
25.

Multimarker risk stratification approach at multiple sclerosis onset.

Fernández-Paredes L, Casrouge A, Decalf J, de Andrés C, Villar LM, Pérez de Diego R, Alonso B, Álvarez Cermeño JC, Arroyo R, Tejera-Alhambra M, Navarro J, Oreja-Guevara C, López Trascasa M, Seyfferth A, García Martínez MA, Álvarez Lafuente R, Albert ML, Sánchez-Ramón S.

Clin Immunol. 2017 Aug;181:43-50. doi: 10.1016/j.clim.2017.05.019. Epub 2017 May 31.

PMID:
28578025
26.

Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation.

González-Suarez I, Rodríguez de Antonio L, Orviz A, Moreno-García S, Valle-Arcos MD, Matias-Guiu JA, Valencia C, Jorquera Moya M, Oreja-Guevara C.

Brain Behav. 2017 Mar 14;7(4):e00671. doi: 10.1002/brb3.671. eCollection 2017 Apr.

27.

Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.

Signori A, Izquierdo G, Lugaresi A, Hupperts R, Grand'Maison F, Sola P, Horakova D, Havrdova E, Prat A, Girard M, Duquette P, Boz C, Grammond P, Terzi M, Singhal B, Alroughani R, Petersen T, Ramo C, Oreja-Guevara C, Spitaleri D, Shaygannejad V, Butzkueven H, Kalincik T, Jokubaitis V, Slee M, Fernandez Bolaños R, Sanchez-Menoyo JL, Pucci E, Granella F, Lechner-Scott J, Iuliano G, Hughes S, Bergamaschi R, Taylor B, Verheul F, Edite Rio M, Amato MP, Sajedi SA, Majdinasab N, Van Pesch V, Sormani MP, Trojano M.

Mult Scler. 2018 Apr;24(5):642-652. doi: 10.1177/1352458517703800. Epub 2017 Apr 6.

PMID:
28382837
28.

Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice.

Spelman T, Meyniel C, Rojas JI, Lugaresi A, Izquierdo G, Grand'Maison F, Boz C, Alroughani R, Havrdova E, Horakova D, Iuliano G, Duquette P, Terzi M, Grammond P, Hupperts R, Lechner-Scott J, Oreja-Guevara C, Pucci E, Verheul F, Fiol M, Van Pesch V, Cristiano E, Petersen T, Moore F, Kalincik T, Jokubaitis V, Trojano M, Butzkueven H; MSBasis (an MSBase Substudy) Investigators.

Mult Scler. 2017 Sep;23(10):1346-1357. doi: 10.1177/1352458516679893. Epub 2016 Nov 25.

PMID:
27885062
29.

Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.

Berger T, Elovaara I, Fredrikson S, McGuigan C, Moiola L, Myhr KM, Oreja-Guevara C, Stoliarov I, Zettl UK.

CNS Drugs. 2017 Jan;31(1):33-50. doi: 10.1007/s40263-016-0394-8. Review.

30.

Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.

Tao C, Simpson S Jr, van der Mei I, Blizzard L, Havrdova E, Horakova D, Shaygannejad V, Lugaresi A, Izquierdo G, Trojano M, Duquette P, Girard M, Grand'Maison F, Grammond P, Alroughani R, Terzi M, Oreja-Guevara C, Sajedi SA, Iuliano G, Sola P, Lechner-Scott J, Pesch VV, Pucci E, Bergamaschi R, Barnett M, Ramo C, Singhal B, LA Spitaleri D, Slee M, Verheul F, Fernández Bolaños R, Amato MP, Cristiano E, Granella F, Hodgkinson S, Fiol M, Gray O, McCombe P, Saladino ML, Sánchez Menoyo JL, Shuey N, Vucic S, Shaw C, Deri N, Arruda WO, Butzkueven H, Spelman T, Taylor BV; MSBase Study Group.

J Neurol Neurosurg Psychiatry. 2016 Dec;87(12):1343-1349. doi: 10.1136/jnnp-2016-314013. Epub 2016 Nov 3.

PMID:
27810919
31.

Analysis of the Relationship between the Month of Birth and Risk of Multiple Sclerosis in a Spanish Population.

Villar-Quiles RN, Matías-Guiu JA, Ortega G, González-Suárez I, Oreja-Guevara C, Matías-Guiu J.

Eur Neurol. 2016;76(5-6):202-209. Epub 2016 Oct 8.

PMID:
27721317
32.

Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis.

Lizak N, Lugaresi A, Alroughani R, Lechner-Scott J, Slee M, Havrdova E, Horakova D, Trojano M, Izquierdo G, Duquette P, Girard M, Prat A, Grammond P, Hupperts R, Grand'Maison F, Sola P, Pucci E, Bergamaschi R, Oreja-Guevara C, Van Pesch V, Ramo C, Spitaleri D, Iuliano G, Boz C, Granella F, Olascoaga J, Verheul F, Rozsa C, Cristiano E, Flechter S, Hodgkinson S, Amato MP, Deri N, Jokubaitis V, Spelman T, Butzkueven H, Kalincik T; MSBase Study Group.

J Neurol Neurosurg Psychiatry. 2017 Mar;88(3):196-203. doi: 10.1136/jnnp-2016-313976. Epub 2016 Sep 28.

PMID:
27683916
33.

[Response to treatment with interferon beta in patients with multiple sclerosis. Validation of the Rio Score].

Rio J, Rovira A, Blanco Y, Sainz A, Perkal H, Robles R, Ramio-Torrenta L, Diaz RM, Arroyo R, Urbaneja P, Fernandez O, Garcia-Merino JA, Reyes MP, Oreja-Guevara C, Prieto JM, Izquierdo G, Olascoaga J, Alvarez-Cermeno JC, Simon E, Pujal B, Comabella M, Montalban X.

Rev Neurol. 2016 Aug 16;63(4):145-50. Spanish.

34.

Defining secondary progressive multiple sclerosis.

Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Hupperts R, Alroughani R, Sola P, Boz C, Pucci E, Lechner-Scott J, Bergamaschi R, Oreja-Guevara C, Iuliano G, Van Pesch V, Granella F, Ramo-Tello C, Spitaleri D, Petersen T, Slee M, Verheul F, Ampapa R, Amato MP, McCombe P, Vucic S, Sánchez Menoyo JL, Cristiano E, Barnett MH, Hodgkinson S, Olascoaga J, Saladino ML, Gray O, Shaw C, Moore F, Butzkueven H, Kalincik T; MSBase Study Group.

Brain. 2016 Sep;139(Pt 9):2395-405. doi: 10.1093/brain/aww173. Epub 2016 Jul 7.

PMID:
27401521
35.

Vitamin D and remyelination in multiple sclerosis.

Matías-Guíu J, Oreja-Guevara C, Matias-Guiu JA, Gomez-Pinedo U.

Neurologia. 2018 Apr;33(3):177-186. doi: 10.1016/j.nrl.2016.05.001. Epub 2016 Jun 16. Review. English, Spanish.

36.

Review of the novelties from the 31st ECTRIMS Congress, 2015, presented at the 8th Post-ECTRIMS meeting.

Fernandez O, Rodriguez-Antiguedad A, Olascoaga J, Oreja-Guevara C, Prieto JM, Mendibe-Bilbao MM, Garcia-Merino JA, Ramio-Torrenta L, Ginestal R, Meca-Lallana JE, Romero-Pinel L, Munoz D, Saiz A, Calles-Hernandez MC, Izquierdo G, Villar LM, Oliva-Nacarino P, Arnal-Garcia C, Comabella M, Brieva L, Arroyo R, Montalban X.

Rev Neurol. 2016 Jun 16;62(12):559-69. Review. English, Spanish.

37.

Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus.

Sepúlveda M, Armangué T, Sola-Valls N, Arrambide G, Meca-Lallana JE, Oreja-Guevara C, Mendibe M, Alvarez de Arcaya A, Aladro Y, Casanova B, Olascoaga J, Jiménez-Huete A, Fernández-Fournier M, Ramió-Torrentà L, Cobo-Calvo A, Viñals M, de Andrés C, Meca-Lallana V, Cervelló A, Calles C, Rubio MB, Ramo-Tello C, Caminero A, Munteis E, Antigüedad AR, Blanco Y, Villoslada P, Montalban X, Graus F, Saiz A.

Neurol Neuroimmunol Neuroinflamm. 2016 Apr 14;3(3):e225. doi: 10.1212/NXI.0000000000000225. eCollection 2016 Jun.

38.

Pittsburgh compound B and other amyloid positron emission tomography tracers for the study of white matter and multiple sclerosis.

Matías-Guiu JA, Cabrera-Martín MN, Oreja-Guevara C, Carreras JL, Matías-Guiu J.

Ann Neurol. 2016 Jul;80(1):166. doi: 10.1002/ana.24666. Epub 2016 May 9. No abstract available.

PMID:
27098362
39.

Amyloid Proteins and Their Role in Multiple Sclerosis. Considerations in the Use of Amyloid-PET Imaging.

Matías-Guiu JA, Oreja-Guevara C, Cabrera-Martín MN, Moreno-Ramos T, Carreras JL, Matías-Guiu J.

Front Neurol. 2016 Mar 31;7:53. doi: 10.3389/fneur.2016.00053. eCollection 2016. Review.

40.

Contribution of different relapse phenotypes to disability in multiple sclerosis.

Stewart T, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Duquette P, Girard M, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Sola P, Shaygannejad V, Hupperts R, Alroughani R, Oreja-Guevara C, Pucci E, Boz C, Lechner-Scott J, Bergamaschi R, Van Pesch V, Iuliano G, Ramo C, Taylor B, Slee M, Spitaleri D, Granella F, Verheul F, McCombe P, Hodgkinson S, Amato MP, Vucic S, Gray O, Cristiano E, Barnett M, Sanchez Menoyo JL, van Munster E, Saladino ML, Olascoaga J, Prevost J, Deri N, Shaw C, Singhal B, Moore F, Rozsa C, Shuey N, Skibina O, Kister I, Petkovska-Boskova T, Ampapa R, Kermode A, Butzkueven H, Jokubaitis V, Kalincik T; MSBase Study Group.

Mult Scler. 2017 Feb;23(2):266-276. doi: 10.1177/1352458516643392. Epub 2016 Jul 11.

PMID:
27055805
41.

Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study.

Martinez-Lapiscina EH, Arnow S, Wilson JA, Saidha S, Preiningerova JL, Oberwahrenbrock T, Brandt AU, Pablo LE, Guerrieri S, Gonzalez I, Outteryck O, Mueller AK, Albrecht P, Chan W, Lukas S, Balk LJ, Fraser C, Frederiksen JL, Resto J, Frohman T, Cordano C, Zubizarreta I, Andorra M, Sanchez-Dalmau B, Saiz A, Bermel R, Klistorner A, Petzold A, Schippling S, Costello F, Aktas O, Vermersch P, Oreja-Guevara C, Comi G, Leocani L, Garcia-Martin E, Paul F, Havrdova E, Frohman E, Balcer LJ, Green AJ, Calabresi PA, Villoslada P; IMSVISUAL consortium.

Lancet Neurol. 2016 May;15(6):574-84. doi: 10.1016/S1474-4422(16)00068-5. Epub 2016 Mar 18.

PMID:
27011339
42.

Amyloid PET imaging in multiple sclerosis: an (18)F-florbetaben study.

Matías-Guiu JA, Cabrera-Martín MN, Matías-Guiu J, Oreja-Guevara C, Riola-Parada C, Moreno-Ramos T, Arrazola J, Carreras JL.

BMC Neurol. 2015 Nov 25;15:243. doi: 10.1186/s12883-015-0502-2.

43.

Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trial.

Villoslada P, Rovira A, Montalban X, Arroyo R, Paul F, Meca-Lallana V, Ramo C, Fernandez O, Saiz A, Garcia-Merino A, Ramió-Torrentà L, Casanova B, Oreja-Guevara C, Muñoz D, Martinez-Rodriguez JE, Lensch E, Prieto JM, Meuth SG, Nuñez X, Campás C, Pugliese M; NeuroAdvan study.

Neurol Neuroimmunol Neuroinflamm. 2015 Sep 10;2(5):e147. doi: 10.1212/NXI.0000000000000147. eCollection 2015 Oct.

44.

Psychotherapeutic and psychosocial interventions for managing stress in multiple sclerosis: the contribution of mindfulness-based interventions.

Muñoz San José A, Oreja-Guevara C, Cebolla Lorenzo S, Carrillo Notario L, Rodríguez Vega B, Bayón Pérez C.

Neurologia. 2016 Mar;31(2):113-20. doi: 10.1016/j.nrl.2015.07.014. Epub 2015 Sep 15. Review. English, Spanish.

45.

Overview of magnetic resonance imaging for management of relapsing-remitting multiple sclerosis in everyday practice.

Oreja-Guevara C; ParadigMS Group.

Eur J Neurol. 2015 Oct;22 Suppl 2:22-7. doi: 10.1111/ene.12800. Review.

PMID:
26374510
46.

Defining reliable disability outcomes in multiple sclerosis.

Kalincik T, Cutter G, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Hupperts R, Oreja-Guevara C, Boz C, Pucci E, Bergamaschi R, Lechner-Scott J, Alroughani R, Van Pesch V, Iuliano G, Fernandez-Bolaños R, Ramo C, Terzi M, Slee M, Spitaleri D, Verheul F, Cristiano E, Sánchez-Menoyo JL, Fiol M, Gray O, Cabrera-Gomez JA, Barnett M, Butzkueven H.

Brain. 2015 Nov;138(Pt 11):3287-98. doi: 10.1093/brain/awv258. Epub 2015 Sep 10.

PMID:
26359291
47.

Review of the novelties from the 2014 ECTRIMS-ACTRIMS Joint Congress, presented at the 7th Post-ECTRIMS Meeting (II).

Fernandez O, Alvarez-Cermeno JC, Arroyo R, Brieva L, Calles-Hernandez MC, Casanova-Estruch B, Comabella M, Garcia-Merino JA, Ginestal R, Izquierdo G, Meca-Lallana JE, Mendibe-Bilbao MM, Montalban X, Munoz-Garcia D, Olascoaga J, Oliva-Nacarino P, Oreja-Guevara C, Ramio-Torrenta L, Romero-Pinel L, Rodriguez-Antiguedad A, Saiz A, Tintore M, Grupo Post-Ectrims GP.

Rev Neurol. 2015 Sep 16;61(6):271-83. English, Spanish.

48.

[Review of the novelties from the 2014 ECTRIMS-ACTRIMS Joint Congress, presented at the 7th Post-ECTRIMS meeting (I)].

Fernandez O, Alvarez-Cermeno JC, Arroyo R, Brieva L, Calles-Hernandez MC, Casanova-Estruch B, Comabella M, Garcia-Merino JA, Ginestal R, Izquierdo G, Meca-Lallana JE, Mendibe-Bilbao MM, Montalban X, Munoz-Garcia D, Olascoaga J, Oliva-Nacarino P, Oreja-Guevara C, Ramio-Torrenta L, Romero-Pinel L, Rodriguez-Antiguedad A, Saiz A, Tintore M, Grupo Post-Ectrims GP.

Rev Neurol. 2015 Sep 1;61(5):215-24. Spanish.

49.

Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry.

Rojas JI, Patrucco L, Trojano M, Lugaresi A, Izquierdo G, Butzkueven H, Jokubaitis V, Duquette P, Girard M, Grand'Maison F, Grammond P, Oreja-Guevara C, Hupperts R, Boz C, Petersen T, Bergamaschi R, Giuliani G, Lechner-Scott J, Barnett M, Rio ME, Van Pesch V, Amato MP, Iuliano G, Fiol M, Slee M, Verheul F, Fernandez-Bolanos R, Poehlau D, Saladino ML, Braber-Moerland LD, Deri N, Oleschko-Arruda W, Cabrera-Gomez JA, Paine M, Vella N, Kister I, Skromne E, Savino A, Shaw C, Moore F, Vucic S, Petkovska-Boskova T, Bacile EAB, Santiago V, Cristiano E.

Mult Scler J Exp Transl Clin. 2015 Aug 17;1:2055217315600193. doi: 10.1177/2055217315600193. eCollection 2015 Jan-Dec.

50.

[Compliance of the guidelines of the Spanish Neurology Society in the treatment of patients with multiple sclerosis].

Oreja-Guevara C, Río J, Gobartt AL; nombre del grupo de investigadores del estudio FUTURA.

Rev Neurol. 2015 Aug 16;61(4):145-52. Spanish.

Supplemental Content

Loading ...
Support Center